Do you consider initiating systemic therapy for patients with NSCLC who develop oligometastatic disease and have all known sites of disease treated with SBRT?

This is a very intriguing and challenging question and addresses a not so uncommon clinical scenario when patients present with one or just a few sites of recurrent disease after delivery of what was considered to be definitive therapy. In such contexts many times it appears appealing and appropriat...